Conference Dates
June 12 – 17, 2022
Abstract
Background: Research efforts during recent decades have demonstrated the suitability of mammalian cell culture platform for influenza vaccine production. Certainly, the potential of this system for a large-scale continuous vaccine manufacturing will enable a faster response to pandemic comparing with traditional egg-based production. Even though great advances have been achieved on the upstream processing of mammalian cell culture produced influenza vaccines, the downstream processing and quality of final product have still room for improvement or is still in development.
Please click Download on the upper right corner to see the full abstract.
Recommended Citation
Amine Kamen, Xingge Xu, Zeyu Yang, Irene González Domínguez, Cécile Toussaint, Alice Bernier, Alina Venereo Sanchez, Omar Famos, and Cristina Aglaia Alves Tottoli e Silva, "Development of scalable downstream processing platform for HEK293SF cell-based influenza vaccine production" in "Vaccine Technology VIII", Tarit Mukhopadhyay, Merck Research Laboratories, USA; Charles Lutsch, Sanofi Pasteur, France; Linda Hwee-Lin Lua, University of Queensland, Australia; Francesc Godia, Universitat Autònoma de Barcelona, Spain Eds, ECI Symposium Series, (2022). https://dc.engconfintl.org/vaccine_viii/124